Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook

Immunotherapy (IO) has revolutionized the therapy landscape of non-small cell lung cancer (NSCLC), significantly prolonging the overall survival (OS) of advanced stage patients. Over the recent years IO therapy has been broadly integrated into the first-line setting of non-oncogene driven NSCLC, eit...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvath, Lena, Thienpont, Bernard, Zhao, Liyun, Wolf, Dominik, Pircher, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488475/
https://www.ncbi.nlm.nih.gov/pubmed/32917214
http://dx.doi.org/10.1186/s12943-020-01260-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488475/
https://www.ncbi.nlm.nih.gov/pubmed/32917214
http://dx.doi.org/10.1186/s12943-020-01260-z

Ejemplares similares